<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081168</url>
  </required_header>
  <id_info>
    <org_study_id>NL68326.029.19</org_study_id>
    <nct_id>NCT04081168</nct_id>
  </id_info>
  <brief_title>COLLISION XL: Unresectable Colorectal Liver Metastases (3-5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation</brief_title>
  <acronym>COLLISION-XL</acronym>
  <official_title>COLLISION XL: Unresectable Colorectal Liver Metastases: Stereotactic Body Radiotherapy vs. Microwave Ablation - a Phase II Prospective Randomized Controlled Trial for Intermediate-size (3 - 5 cm) Colorectal Liver Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple articles report that thermal ablation is a safe and effective treatment for&#xD;
      unresectable colorectal liver metastases (CRLM) ≤3cm. However efficacy of thermal ablation&#xD;
      decreases with increasing lesion size. Guidelines state that thermal ablation is the&#xD;
      preferred option for unresectable CRLM ≤3cm and stereotactic body radiotherapy (SBRT) when&#xD;
      thermal ablation is not possible. It remains uncertain what local treatment method should be&#xD;
      recommended for unresectable CRLM of 3-5cm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The primary objective of this study is to compare efficacy of MWA to the efficacy&#xD;
      of SBRT with regards to the primary endpoint (local tumour progression free survival at 1&#xD;
      year [1-year LTPFS]) in patients with unresectable CRLM (3 - 5 cm) that are unsuitable for&#xD;
      surgery due to either comorbidities, a history of extensive abdominal surgery, a poor&#xD;
      performance status or due to a certain unfavourable anatomical location of the tumour.&#xD;
&#xD;
      Study design: COLLISION XL is a prospective multi-centre phase-II randomized controlled&#xD;
      trial.&#xD;
&#xD;
      Study population: 68 patients with 1-3 unresectable lesions of 3 - 5cm, unsuitable for&#xD;
      (further) chemotherapy regimens, suitable for both MWA and SBRT and no or limited&#xD;
      extrahepatic disease (1 extrahepatic lesion is allowed, not including positive para-aortal&#xD;
      lymph nodes, celiac lymph nodes, adrenal metastases, pleural carcinomatosis or peritoneal&#xD;
      carcinomatosis) are considered eligible. Supplementary resections for resectable lesions and&#xD;
      thermal ablations for unresectable CRLM ≤3cm are allowed. A maximum number of 10 CRLM are&#xD;
      allowed for patients with no extrahepatic disease and a maximum number of 5 lesions are&#xD;
      allowed for patients with limited extrahepatic disease.&#xD;
&#xD;
      Intervention: SBRT or MWA. The panel, consisting of at least two interventional radiologists,&#xD;
      two hepatobiliary surgeons and two radiation oncologists, will appoint lesions of 3-5cm that&#xD;
      are unresectable and suitable for both MWA and SBRT, as target lesions. All lesions that are&#xD;
      not suitable for ablation should be resectable and all unresectable lesions &lt;3cm should be&#xD;
      suitable for thermal ablation.&#xD;
&#xD;
      Main study parameters/endpoints: Primary endpoint is local tumour progression free survival&#xD;
      (LTPFS) at 1 year from randomization. Secondary endpoints are local tumour progression free&#xD;
      survival time, OS, disease-free survival (DFS), time to progression (TTP), procedural&#xD;
      morbidity/toxicity and mortality, assessment of pain and quality of life (QoL) and&#xD;
      cost-effectiveness ratio (ICER).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2019</start_date>
  <completion_date type="Anticipated">January 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Stereotactic Body Radiotherapy vs. Microwave Ablation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>One-year local tumor progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <description>One-year local tumor progression-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timo-to-local tumor progression</measure>
    <time_frame>5 years</time_frame>
    <description>Timo-to-local tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-Free Survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-Free Survival (DFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>Mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <condition>Liver Metastasis Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients included will undergo Stereotactic Body Radiotherapy (SBRT) of hepatic metastases.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microwave Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients included will undergo Microwave Ablation (MWA) of hepatic metastases.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>Patients will undergo Stereotactic Body Radiotherapy (SBRT)</description>
    <arm_group_label>Stereotactic Body Radiotherapy</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Microwave Ablation</intervention_name>
    <description>Patients will undergo Microwave Ablation (MWA)</description>
    <arm_group_label>Microwave Ablation</arm_group_label>
    <other_name>MWA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1-3 unresectable CRLM size 3-5 cm eligible for both MWA and SBRT (target lesions);&#xD;
&#xD;
          -  Additional CRLM are allowed if considered either resectable or ablatable and &lt;3cm&#xD;
&#xD;
          -  No or limited extrahepatic disease (1 extrahepatic lesion is allowed, not including&#xD;
             positive para-aortal lymph nodes, celiac lymph nodes, adrenal metastases, pleural&#xD;
             carcinomatosis or peritoneal carcinomatosis);&#xD;
&#xD;
          -  For subjects with liver only disease the maximum number of CRLM is 10; for subjects&#xD;
             with limited extrahepatic disease the maximum number of CRLM is 5;&#xD;
&#xD;
          -  Prior focal liver treatment is allowed&#xD;
&#xD;
          -  Subjects without prior focal liver treatment should be either unsuitable for 1st line&#xD;
             chemotherapy or have progressed under/after 1st-line chemotherapy;&#xD;
&#xD;
          -  Subjects with recurrent (either local or distant-hepatic) CRLM after previous focal&#xD;
             treatment should be unsuitable for (further) systemic therapy (further downsizing or&#xD;
             conversion to resectable disease improbable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Compromised liver function (e.g. signs of portal hypertension, INR &gt; 1,5 without use&#xD;
             of anticoagulants, ascites);&#xD;
&#xD;
          -  Pregnant or breast-feeding subjects;&#xD;
&#xD;
          -  Immunotherapy ≤ 6 weeks prior to the procedure;&#xD;
&#xD;
          -  Chemotherapy ≤ 6 weeks prior to the procedure;&#xD;
&#xD;
          -  Severe allergy to contrast media not controlled with premedication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>S. Nieuwenhuizen, MD</last_name>
    <phone>+31204443047</phone>
    <email>s.nieuwenhuizen1@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>M.R. Meijerink, MD, PhD</last_name>
    <phone>+31204443047</phone>
    <email>mr.meijerink@amsterdamumc.nl</email>
  </overall_contact_backup>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. M.R. Meijerink</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

